To: Steve Lokness who wrote (658 ) 4/18/1998 3:18:00 PM From: Richard Haugland Read Replies (1) | Respond to of 1728
Steve: AFFX shot up just at the end again Friday from 30 to 31 before closing at 30 1/2 whereas VGINF shot down. I sold some VGINF earlier in the week at 9 3/8 and 9 1/2 and have been buying AFFX at ~30 and selling it again at ~31. I plan to buy some VGINF back at a lower price, if it descends, as in the past because I expect its earnings report to be quite optimistic, even if its net earnings are still negative. Just missed selling the AFFX late Friday I bought on Wednesday. Unfortunately I was out when it rose from about 31 to over 35 but then I was also out while it came back below 31 (except one profitable day trade). I am really too heavy in genetic (and other) screening now with AFFX, MLNM, ABSC, MDYN, VGINF and VYSI (Vysis) stock with this being >50% of my portfolios (mostly because I have been buying MLNM as it continues to descend). VYSI, which is newly public, looks good in a fairly short period (a few years to profitability at the most). VYSI just won a major case from Oncor that sustained its licensed patents (from U Ca) in Fluorescence in situ Hybridization (FISH) and it has several products either approved or in the pipeline. VYSI also got royalties from Oncor, the non-oncology business from Oncor (~$3,000,000 revenues a year) and $3,000,000 dollars (probably minus the pile its lawyers will get). It was started at AMOCO, which still owns a fair amount of stock. The stock initially sold at $12 and has descended to about $10.50. Few people watch it so far, I believe. My other BIO holding is ENMD, which suddenly moved from $12 (low of 11 3/8 intraday) to $13 on Friday on relatively high volume (4x normal), with the last half dollar in the last 2 minutes (through my sell day-order for some shares at 12 3/4). According to a friend at Mayo whom I trust, their products under development (tumor treatment drugs) are extremely promising if they can scale up production and are being given expedited evaluation at the NIH.